跳至主要内容
临床试验/NCT05290688
NCT05290688尚未招募不适用

Cellular microRNA Signatures in Multiple Sclerosis

Institut Pasteur2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年9月15日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
20
试验地点
2
主要终点
microRNA expression profiles in immune cell populations from RRMS patients

研究概览

简要总结

A limited number of studies on microRNA expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (RRMS). These studies have been performed mostly on a small scale and on whole blood mononuclear cells (PBMC).

In a number of cases, RRMS progresses to a severe secondary neurodegenerative form. In this context, it is important to look for biomarkers that could indicate the pathogenic activity of certain immune cell subpopulations.

详细描述

SEP-MIR is a prospective, single-center, descriptive study.

Participants will be recruited among adult patients with RRMS coming for a follow-up consultation in the Neurology Department, Nervous System Diseases Pole, at the hôpital Pitié - Salpêtrière (Paris).

As this is a descriptive study, the recruitment of 20 participants (10 patients with relapsing-remitting MS and 10 patients with relapsing-remitting MS) should meet the objectives of this study.

A 50 ml blood sample will be obtained from each participant and several clinical data regarding their pathology will be collected.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Caucasian population
  • Female and male individuals with an f/m ratio of 2-4/1
  • Individuals with RRMS according to the 2010 McDonald criteria for less than 15 years, with EDSS 1-6, in remission or relapse
  • Participant's condition compatible with a maximum of 50 ml of blood collection
  • Persons affiliated with a social security plan.

排除标准

  • MS treatment with steroidal anti-inflammatory drugs, immunomodulators or immunosuppressants within 2 months prior to blood collection
  • Persons with acute and chronic infectious disease, autoimmune/inflammatory disease or cancer other than MS
  • Pregnant or lactating women
  • Be under guardianship,
  • Be deprived of liberty by judicial or administrative decision, or be under legal protection.

结局指标

主要结局

microRNA expression profiles in immune cell populations from RRMS patients

时间窗: 2 years

RNAseq and/or Nanostring sequencing of PBMCs from RRMS patients

次要结局

  • microRNA expression profiles in unstimulated and stimulated CD4+ T cell populations ex vivo from RRMS patients(2 years)
  • microRNA expression profiles in monocytes from RRMS patients(2 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验